Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Therapeutic Body Modification Clear all
Active, not recruiting Early Phase 1 Interventional Results available

Ruxolitinib for Cancer Cachexia

NCT04906746
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Cachexia
Interventions
Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
Drug
Lead sponsor
Tu Dan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Terminated Not applicable Interventional Results available

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

NCT00769652
View directory record Official record
Conditions
Lung Cancer, Malnutrition, Pancreatic Cancer, Prostate Cancer, Weight Changes
Interventions
Medical nutrition therapy, Standard Care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jul 22, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss

NCT00471172
View directory record Official record
Conditions
Obesity
Interventions
Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week), Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week), Self help
Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
25 Years to 60 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Los Angeles, California • Clearwater, Florida • Kissimmee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2008 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
Interventions
ponsegromab, Placebo for ponsegromab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Conway, Arkansas • Little Rock, Arkansas • North Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients

NCT01174706
View directory record Official record
Conditions
Patient Compliance, Medication Adherence, Medication Non-Adherence
Interventions
Information prescriptions
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
3,940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jul 22, 2026, 2:06 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations

NCT00487344
View directory record Official record
Conditions
Obesity
Interventions
Non-Personalized Meal Planning, Personalized Meal Planning and Dietetic Consultation
Procedure
Lead sponsor
Central FITT, Inc
Other
Eligibility
25 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Edmond, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

NCT03946111
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
Naltrexone and Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Regimen for the Treatment of Cachexia in Subjects With NSCLC

NCT00527319
View directory record Official record
Conditions
Cachexia
Interventions
VT-122 low dose, VT-122 high dose
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

NCT00039195
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

NCT01387269
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Fullerton, California • Glendale, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss

NCT02518685
View directory record Official record
Conditions
Obesity
Interventions
TransPyloric Shuttle, Sham procedure, Lifestyle Counseling
Device · Behavioral
Lead sponsor
BaroNova, Inc.
Industry
Eligibility
22 Years to 60 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 22, 2026, 2:06 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity

NCT05713071
View directory record Official record
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional

YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03512184
View directory record Official record
Conditions
Weight Loss, NAFLD, Liver Diseases
Interventions
YMCA class
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 22, 2026, 2:06 PM EDT
Active, not recruiting Not applicable Interventional Results available

Lymphocyte Depletion and Change in Lymphocyte Functionality

NCT04273893
View directory record Official record
Conditions
Lymphocyte Depletion
Interventions
SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
Radiation · Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals

NCT01862796
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Underfeeding diet, Weight maintaining diet
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263
View directory record Official record
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 3 Interventional

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

NCT00040885
View directory record Official record
Conditions
Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions
infliximab, docetaxel, placebo
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
188
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 2:06 PM EDT
Recruiting Not applicable Interventional

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821
View directory record Official record
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

NCT04599504
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Lisdexamfetamine Dimesylate (Medication), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

NCT01387282
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
14
States / cities
Corona, California • Fountain Valley, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 22, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EMS for Abdominal and Gluteal Muscle Toning

NCT03983304
View directory record Official record
Conditions
Non-Therapeutic Body Modification
Interventions
The ZELTIQ EMS System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Marina del Rey, California • Pleasanton, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 22, 2026, 2:06 PM EDT